{"id":"NCT02192814","sponsor":"UCB Japan Co. Ltd.","briefTitle":"Open-label Study to Evaluate the Safety and Tolerability of iv Lacosamide in Japanese Adults With Partial-onset Seizures","officialTitle":"A Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Intravenous Lacosamide as Replacement for Oral Lacosamide in Japanese Adults With Partial-onset Seizures With or Without Secondary Generalization","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-06","primaryCompletion":"2014-10","completion":"2014-12","firstPosted":"2014-07-17","resultsPosted":"2015-12-04","lastUpdate":"2017-08-25"},"enrollment":9,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy","Partial-onset Seizures"],"interventions":[{"type":"DRUG","name":"Lacosamide (200 mg/20 mL)","otherNames":["Vimpat"]}],"arms":[{"label":"Lacosamide (LCM)","type":"EXPERIMENTAL"}],"summary":"EP0024 is a Phase 3, multicenter, open-label study to evaluate the safety and tolerability of intravenous (iv) lacosamide (LCM). Adjunctive iv LCM therapy (200 mg/day to 400 mg/day) will be administered for 5 days as replacement for oral LCM tablets in Japanese adults with partial-onset seizures.","primaryOutcome":{"measure":"The Total Number of Subjects Experiencing at Least One Adverse Event During the Study","timeFrame":"During the study (Screening through End of Study (Day -1 through Day 6))","effectByArm":[{"arm":"Lacosamide (LCM)","deltaMin":4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":5,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":9},"commonTop":["Abdominal pain upper","Toothache","Vomiting","Injection site erythema","Injection site pain"]}}